ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

10,080.00
97.00 (0.97%)
01 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  97.00 0.97% 10,080.00 10,096.00 10,098.00 10,114.00 10,002.00 10,046.00 2,733,830 16:35:12
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 26.29 156.54B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 9,983p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,390.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £156.54 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 26.29.

Astrazeneca Share Discussion Threads

Showing 5651 to 5672 of 6125 messages
Chat Pages: Latest  233  232  231  230  229  228  227  226  225  224  223  222  Older
DateSubjectAuthorDiscuss
25/4/2022
06:49
Big news on the liver cancer trial this morning.
hotfinance14
19/4/2022
07:13
AstraZeneca PLC and Daiichi Sankyo Co. said Tuesday that Enhertu, a cancer treatment, has been accepted by the U.S. Food and Drug Administration for priority review for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease and the designation shortens the review period.

The pharmaceutical companies said the FDA based its decision on a pivotal Destiny-Lung01 trial which showed that Enhertu was the first HER2-directed therapy to show a strong and robust tumor response. It added that the FDA action date for their regulatory decision is during the third quarter of 2022.

The HER2 protein is expressed on the surface of many types of tumors and is one of many biomarkers expressed in breast cancer tumors.

"Enhertu is being further assessed in a comprehensive clinical development program evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers," AstraZeneca said.



Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com



(END) Dow Jones Newswires

April 19, 2022 02:40 ET (06:40 GMT)

maywillow
12/4/2022
17:09
Filled the gaps nicely on the chart
gateside
12/4/2022
16:58
Had a superb run, just a bit of profit taking.
montyhedge
12/4/2022
11:44
ASTRAZENECA : Buy rating from Berenberg
04/12/2022 | 12:40pm BST

In a research note published by Luisa Hector, Berenberg advises its customers to buy the stock. The target price is revised upwards from GBX 10000 to GBX 12000.

waldron
08/4/2022
18:40
have not followed this stock for a while - what a mistake . now chart shows a NOR situation and how long is s piece of string !
arja
08/4/2022
15:27
Long term, holder, yes institutions must be piling in with new cash.
chc15
08/4/2022
15:03
Institutions I assume. I bought a fair amount, in my terms before the rise and am happily holding.
our haven
08/4/2022
14:45
I'm buying it...
mapocho
08/4/2022
13:43
Amazed there is so little chatter on this board. Up 25% in a month. Keeping entire FTSE up whilst Europe and US markets fall.But no interest here? Who is buying this?
paa65
07/4/2022
06:37
James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating.


The target price is reviewed upwards from GBX 10000 to GBX 12000.

la forge
06/4/2022
16:00
Analysts at Deutsche Bank hiked their target price for AstraZeneca shares from 10,500.0p to 11,500.0p, telling clients it saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'.

Deutsche Bank conceded that an environment of rising interest rates would normally hardly be seen as auguring positively for a defensive sector to outperform.

However, DB highlighted that these weren't exactly normal times.

"This being a geopolitically-challenged stagflationary-susceptible situation, normal perhaps doesn't apply and indeed pharma has had a strong relative start to the year that may well continue," explained DB.

Within the sector, more highly-valued growth names such as AstraZeneca and Novo Nordisk had been the standout outperformers, versus the likes of GlaxoSmithKline, Novartis or Sanofi.

misca2
06/4/2022
09:09
Deutsche Bank raises AstraZeneca price target to 11,500 (10,500) pence - 'buy'
philanderer
05/4/2022
15:24
As mentioned, big momentum here, institutions buying at this level, so why sell.
chc15
05/4/2022
14:59
WD Waldron, good forecast!
dudishes
05/4/2022
06:15
Todays the day it might well break thru an important Resistence level
waldron
05/4/2022
06:14
(MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday its AZD8233 drug at 50-milligram dose lowered the levels of low-density lipoprotein cholesterol by 73% among people with high-risk hypercholesterolemia, meeting the main goal of a phase 2b study.

The dose-ranging clinical trial, dubbed Etesia, evaluated AZD8233 at 15 mg, 50 mg and 90 mg doses administered monthly via subcutaneous injection within a 12-week period.

Results showed that the drug also cut the PCSK9 enzyme levels by 89%, with sustained reductions observed over the dosing intervals. A decrease in PCSK9 raises LDL receptor levels, which in turn lowers cholesterol levels in the bloodstream, reducing the risk of developing heart disease.

The safety, efficacy and tolerability of AZD8233 in hypercholesterolemia are being examined in the Solano phase 2b trial, with results expected later in the year.

AstraZeneca gained nearly 1% on Monday's close.

Price (GBP): £10142.00, Change: £+66.00, Percent Change: +0.66%

waldron
31/3/2022
17:44
Mind u, mkts going down after putins demands, so taking profits not a bad thing.
chc15
31/3/2022
17:15
No harm in taking profits, but feel there is good momentum here.
chc15
31/3/2022
14:48
I'm out at £102. This is above quite a few broker PT's so happy to take profits.
Currently way above 20 mda, too high too quickly, will buy back when it settles.
Good Luck all.

beckers2008
31/3/2022
11:22
We surging here, can only mean there is strong institutional buying at this level, wow.
chc15
29/3/2022
13:09
Azn holders now in the 100 club..olaay olay olay.
hotfinance14
Chat Pages: Latest  233  232  231  230  229  228  227  226  225  224  223  222  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com